Table 1.
Clinical characteristics of patients and controls included in the study.
| Controls | TSHomas | RTHβ | P | |
|---|---|---|---|---|
| N | 105 | 26 | 61 | |
| Males/females (n) | 36/69 | 9/17 | 16/45 | NS |
| AITD (n) | 31 | 5 | 21 | NS |
| Age (years) | 39 ± 15 | 42 ± 13 | 34 ± 15 | <0.05*; NS#§ |
| Baseline TSH (μUI/ml) | 2.3 ± 1.6 | 3.5 ± 2.6 | 2.4 ± 2.0 | NS*; <0.05#§ |
| Baseline FT4 (pmol/l) | 12.6 ± 2.8 | 28.1 ± 6.7 | 32.2 ± 12.2 | <0.05*#; NS§ |
| Baseline FT3 (pmol/l) | 5.4 ± 1.2 | 11.1 ± 3.8 | 10.1 ± 4.3 | <0.05*#; NS§ |
| Expansive lesions at pituitary MRI | 4/25 | 20/26 | 11/45 | <0.001#§; NS* |
| TRH test (n) | 103 | 24 | 61 | |
| TSH peak (μUI/ml) | 16.7 ± 12.4 | 7.7 ± 7.2 | 19.0 ± 13.1 | <0.001#§; NS* |
| TSH fold increase | 7.8 ± 3.3 | 2.3 ± 1.6 | 9.3 ± 4.9 | <0.001#§* |
| delta increase TSH (μUI/ml) | 14.4 ± 11.2 | 3.9 ± 5.6 | 16.5 ± 11.5 | <0.001#§; NS* |
| T3 suppression (n) | 15 | 19 | 16 | |
| TSH (μUI/ml) at day 10 | 0.02 ± 0.02 | 1.9 ± 1.5 | 0.3 ± 0.5 | <0.0001#§; NS* |
Data are expressed as mean ± SD; abnormal values are indicated in bold.
*
Between RTHβ and controls;
§
between RTHβ and TSHoma;
#
between TSHoma and controls. IST, inappropriate secretion of TSH; FDH, Familial Dysalbuminemic Hypothyroxinemia; MRI, magnetic resonance imaging; AITD, autoimmune thyroid disorders. Test: one way ANOVA, chi-square test.
Reference ranges: TSH 0.3–5.1 mU/L; FT4 10–20 pmol/L; FT3 4.2–7.5 pmol/L.